Ocular Therapeutix, Inc. ( OCUL) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDT Ocular Therapeutics. Presenting for Ocular today and sitting up on stage with me is Dr.

Researchers have identified distinct biological features linked to a high risk of developing a severe form of age-related ...

Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved ...

Purpose The cross-sectional and longitudinal associations between accelerated biological ageing and the risk of cataract and ...

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...

A phase III trial found that the sustained-release VEGF inhibitor implant OTX-TKI preserved visual acuity and retinal anatomy in wet age-related macular degeneration better than standard aflibercept ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with advanced dry macular degeneration. The hair-thin patch replaces damaged retinal ...

Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

All 12 analysts covering the stock rate it a buy, with a mean price target of $37.17—implying 168% upside from Monday’s close of $13.85. Revenue estimates have risen 12% over the past 60 days, though ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that 36-month results from ...